155 related articles for article (PubMed ID: 37592092)
21. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
[TBL] [Abstract][Full Text] [Related]
22. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Brümmendorf TH; Cortes JE; Milojkovic D; Gambacorti-Passerini C; Clark RE; le Coutre P; Garcia-Gutierrez V; Chuah C; Kota V; Lipton JH; Rousselot P; Mauro MJ; Hochhaus A; Hurtado Monroy R; Leip E; Purcell S; Yver A; Viqueira A; Deininger MW;
Leukemia; 2022 Jul; 36(7):1825-1833. PubMed ID: 35643868
[TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
[TBL] [Abstract][Full Text] [Related]
24. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Crescenzo R; Mamolo C; Reisman A; Hochhaus A; Brümmendorf TH;
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1589-1599. PubMed ID: 30989330
[TBL] [Abstract][Full Text] [Related]
25. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.
Ono T; Hino M; Matsumura I; Fujisawa S; Ishizawa K; Sakaida E; Sekiguchi N; Ono C; Aizawa M; Tanetsugu Y; Koide Y; Takahashi N
Int J Hematol; 2022 Dec; 116(6):871-882. PubMed ID: 35963986
[TBL] [Abstract][Full Text] [Related]
26. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
27. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
Isfort S; Crysandt M; Gezer D; Koschmieder S; Brümmendorf TH; Wolf D
Recent Results Cancer Res; 2018; 212():87-108. PubMed ID: 30069626
[TBL] [Abstract][Full Text] [Related]
28. Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Latagliata R; Attolico I; Trawinska MM; Capodanno I; Annunziata M; Elena C; Luciano L; Crugnola M; Bergamaschi M; Bonifacio M; Baratè C; Mauro E; Binotto G; Sgherza N; Aguzzi C; Monteleone B; Sorà F; Caocci G; Luzi D; Mariggiò E; Scaffidi L; Cattaneo D; Gozzini A; Di Veroli A; Abruzzese E; Galimberti S; Iurlo A; Specchia G; Breccia M
Hematol Oncol; 2021 Aug; 39(3):401-408. PubMed ID: 33617659
[TBL] [Abstract][Full Text] [Related]
29. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
[TBL] [Abstract][Full Text] [Related]
30. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
Takahashi N; Nakaseko C; Kobayashi Y; Miyamura K; Ono C; Koide Y; Fujii Y; Ohnishi K
Int J Hematol; 2017 Sep; 106(3):398-410. PubMed ID: 28409328
[TBL] [Abstract][Full Text] [Related]
31. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.
Hsyu PH; Mould DR; Upton RN; Amantea M
Cancer Chemother Pharmacol; 2013 Jan; 71(1):209-18. PubMed ID: 23070145
[TBL] [Abstract][Full Text] [Related]
33. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.
Cortes JE; Muresan B; Mamolo C; Cappelleri JC; Crescenzo RJ; Su Y; Gambacorti-Passerini C; Heeg B; Douglas Smith B
Curr Med Res Opin; 2019 Sep; 35(9):1615-1622. PubMed ID: 30964361
[No Abstract] [Full Text] [Related]
34. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
[TBL] [Abstract][Full Text] [Related]
35. Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.
Brümmendorf TH; Gambacorti-Passerini C; Bushmakin AG; Cappelleri JC; Viqueira A; Reisman A; Isfort S; Mamolo C
Ann Hematol; 2020 Jun; 99(6):1241-1249. PubMed ID: 32307568
[TBL] [Abstract][Full Text] [Related]
36. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
Takahashi N; Cortes JE; Sakaida E; Ishizawa K; Ono T; Doki N; Matsumura I; García-Gutiérrez V; Rosti G; Ono C; Ohkura M; Tanetsugu Y; Viqueira A; Brümmendorf TH
Int J Hematol; 2022 Jun; 115(6):838-851. PubMed ID: 35235189
[TBL] [Abstract][Full Text] [Related]
37. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH
Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349
[TBL] [Abstract][Full Text] [Related]
39. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
40. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
Imamura K; Izumi Y; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Egawa N; Ayaki T; Oki R; Fujita K; Uozumi R; Morinaga A; Hirohashi T; Fujii Y; Yamamoto T; Tatebe H; Tokuda T; Takahashi N; Morita S; Takahashi R; Inoue H
EClinicalMedicine; 2022 Nov; 53():101707. PubMed ID: 36467452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
